Drug intelligence / Profile preview

Shenghui Yizhi decoction

Development stage: Preclinical
Lead developer: Guiyang University of Chinese Medicine
Modality: Small Molecules
Administration: Oral

Overview

Shenghui Yizhi decoction (SHYZD) is a Traditional Chinese Medicine (TCM) herbal formula primarily investigated for its therapeutic potential in Alzheimer's disease. Grounded in the TCM theory of "coordinating the heart and kidney," SHYZD aims to improve cognitive and learning deficits. Its pharmacological action is largely attributed to its ability to suppress neuroinflammation by inhibiting the NF-κB/NLRP3 signaling pathway. Clinical and preclinical observations suggest it can ameliorate existing neuroinflammatory markers and enhance cognitive performance in patients with Alzheimer's disease.

Brand names: Shenghui Yizhi Tang
Other names: Shenghui Yizhi Decoction

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)NF-κB

Beyond the preview

Go deeper on Shenghui Yizhi decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenghui Yizhi decoction.

Explore the full profile